1[1]Van Cutsem E,Findlay M,Osterwalder B,et al.Capecitabine,an oral fluoropyrimidine carbamate with substantil activity in advanced colorectal cancer;results of a randomized phase Ⅱ study.J Clin Oncol,2000,18:1337-1345
2[3]Kang HJ,Chang HM,kim TW,et al.phase Ⅱ study of capeci-tabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy.British J Cancer,2005,18:1-6
3[4]Jin ML,Shen L,Hu B,et al.Capecitabine (X) combined with fractionated cisplatin (C) as first-line therapy in Chinese patients (pts) with advanced gastric carcinoma (AGC).Proc Am Soc Clin Oncol,2005,23:321
4[5]Kang H,Kim T,Chang H,et al.A phase Ⅱ study of paclitaxel and capecitabine combination chemotherapy in patients with advanced gastric cancer as a first-line therapy.Proc Am Soc Clin,2004,23:325
5[6]Kim H,Chun J,Lee J,et al.A phase Ⅱ study of weekly docetaxel (CT) and capecitabine (X) in patients with metastatic gastric cancer (GC).Proc Am Soc Clin Oncol,2004,23:326
6[7]Peters GJ,Noordhuis P,Van Kuilenburg ABP,et al.Pharmacokinetics of S-1,an oral formulation of ftorafur,oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.Cancer Chemother pharmacol,2003,52:1-12
7[8]koizumi W,Tanabe S,Saigenji K,et al.Phase Ⅰ/Ⅱ study of S-1 combined with cisplatin in patients with advanced gastric cancer.Br J Cancer,2003,89(12):2207-2212
8[10]Ajani JA,Fodor MB,Tjulandin SA,et al.Phase Ⅱ multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated,advanced gastric or gastroesophageal adenocarcinoma.J Clin Oncol,2005,23 (24):5660-5667
9[11]Sumpter K,Harper-Wynne C,Cunningham D,et al.Randomised multicentre phase Ⅲ study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophago gastric cancer receiving ECF:confirmation of dose escalation.Proc Am Soc Clin Oncol,2003,22:1031
10[12]Pozzo C,Bugat R,Peschel C,et al.Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma:final results of a randomized phase Ⅱ study.Proc Am Soc Clin Oncol,2001,20:531
